Introduction
The greatest triumph of medicine is to prevent or abolish disease, but it may be the tragedy of a great originator that this very triumph tends to make him forgotten. Few people are interested in dead dragons, however grateful they may be to the rescuirg St. George while their hair is actually being singed by smoke and fire. It is true enough of tuberculosis that we have scotched the snake, not killed it, and that the disease is still an enormous problem in many countries, but its present relative control in Britain might lead us to forget some of the pioneers who fought the dragon while he was in his prime.
This lecture is founded in honour of a great statesman of medicine, a man with a capacity to inspire and organize both doctors and laymen in the service of sick people. The system of co-ordinated prevention and treatment of tuberculosis which Philip initiated in Edinburgh only five years after Koch discovered the tubercle bacillus-and only five years after he himself had qualified in medicine-was copied throughout Britain ' and throughout the world (Clayson, 1957 ; Williams, 1957 Goldberg (1965) , Ca!rter and McCarty (1966) , and Sanders and Cluff (1968) (Fig. 4) (Perkins, 1963) . This accounts for the lack of toxicity of penicillin and cephaloridine to host cells. The actual destruction of the cell wall is probably effected by bacterial mucopeptidases, the normal function of which is to lyse the inner part of the wall in the growing cell so as to allow the increasing cytoplasm to expand, the outer part of the wall being enlarged by a synthesis as the cell grows.
In relatively low concentrations penicillin has no inhibitory effect on protein production, so that the cell continues to BREICLr MEDICAL JOURNAus produce mucopeptidases (Rogers, 1967) . This accounts for the fact that, under experimental conditions, it may be an hour or more before penicillin begins killing the bacteria; during this period the effect of penicillin is reversible if the antibiotic is removed (Pennington and O'Grady, 1967) . The process also probably accounts for the antagonistic effect of chloramphenicol on the bactericidal action of penicillin under experimental conditions. Chloramphenicol interferes with the manufacture of the mucopeptidases necessary to complete the destruction of the cell wall (Rogers, 1967 (Newton, 1954; Sanders and Cluff, 1968) .
Synergism and Antagonism Between Drugs
In in-vitro studies Jawetz and Gunnison (1953) showed that if two bactericidal drugs were used together in concentrations which, with each drug alone, were only marginally effective, the bactericidal effect could be dramatically increased. The same thing could be shown with experimental infections, again provided marginal doses were used. The effect was demonstrable only with certain organisms. It may be due to a double effect on two metabolic processes, but the elimination of L-form persisters (see below) might play a part (Hewitt and Deigh, 1965) .
In most infections it is unnecessary to use two drugs in combination for their synergistic effect, because a single drug is highly successful provided the organism is sensitive to it. But in certain infections which are difficult to eliminate the combination of two bactericidal drugs may be particularly useful. A well-known example is the superiority of penicillin combined with streptomycin in the treatment of enterococcal bacterial endocarditis, though experimental work suggests that penicillin with kanamycin might be even more effective (Hewitt and Deigh, 1965 (Jawetz, 1964) . There is one often-quoted report in which it is suggested that the effect of penicillin in pneumococcal meningitis was diminished by the simultaneous administration of a tetracycline drug (Lepper and Dowling, 1951 Natural drug resistance may be characteristic of an entire species, but sometimes, as in the case of penicillin resistance in staphylococci, is confined to particular strains of that species. It may be due to (1) the absence of the metabolic process which is affected by the drug in question, (2) a structural peculiarity, such as the absence of cell wall in mycoplasmata which renders them resistant to penicillin, or (3) the production of enzymes which destroy the drug, as in the production of penicillinase by staphylococci. When one considers that a number of antibiotics act by having a complex structural peculiarity which enables them to mimic a naturally occurring molecule essential to a metabolic process, and so block that process like a bent key in a lock, it is easy to see that a slight change in a bacterial molecule might prevent the bent key getting into the lock at all. For instance, both the tetracyclines and erythromycin interfere with the attachment of the amino-acid-tR.N.A. complex to the mR.N.A.-ribosome complex (Fig. 4) ; but the tetracyclines are highly effective against many Gram-negative bacilli unaffected by erythromycin. This suggests that the two drugs must interfere with the process in different ways, and that erythromycin does not fit this particular metabolic lock in the case of most Gram-negative organisms.
Sulphonamides act by interfering with an enzyme which synthesizes tetrahydropteroic acid from para-aminobenzoic acid and another substrate. The action of the drug can be prevented by introducing an excess of para-aminobenzoic acid, which most sulphonamide-sensitive organisms require to obtain from their environment. A strain may be resistant to sulphonamides because it actually produces the para-aminobenzoic acid itself, or because it has a different enzyme less sensitive to sulphonamide, or because of a lesser permeability which reduces the penetration of the sulphonamide into the bacterial cell (Richmond, 1966 McCarty, 1966) . The possibility of L-forms being concerned with the phenomenon of persistence (see below) and relapse after treatment requires further investigation.
The production of antibiotic-destroying enzymes, of which penicillinase is the best known, may reflect a natural weapon in the ecological struggle between micro-organisms. The evolution of antibiotics by, for instance, fungi-may tend to destroy species which are rivals for the supply of nourishment. The evolution of antibiotic-destroying enzymes would be a protective mechanism. In a hospital environment in which a particular antibiotic is intensively used the possession by a mutant strain of an enzyme destroying that antibiotic is clearly of survival value, and this largely accounts for the ecological success of the penicillin-resistant hospital staphylococcus. Bacterial strains or species resistant to the chemotherapeutic agents commonly used in a particular environment are naturally the ones which will tend to survive in this environment and to replace sensitive strains. Unfortunately there is a possibility that this process of natural selection may be accelerated by the transfer or transduction of resistance-conferring genetic material from resistant to sensitive strains or species (see below).
It is important, therefore, that certain drugs should be reserved for treating resistant strains. When drugs such as cloxacillin or methicillin are used for treating an infection with staphylococci known or suspected to be resistant to the usual drugs, it is our own custom to trdat the patient in isolation with barrier nursing so as to minimize the chances of the emergence of strains resistant to the reserve drugs.
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If the production of penicillinase can be decreased by inhibiting bacterial metabolism with a penicillinase-resistant penicillin, enough benzylpenicillin may survive, if given at the same time, to affect the bacteria which, in the case of staphylococci, are resistant to it only by reason of penicillinase production. Weight for weight benzylpenicillin is much more effective than methicillin or cloxacillin. Moreover, there is also evidence that penicillinase may be bound 1y rpethicillin and so prevent its action against benzylpenicillin (v arrar et al., 1967) . Even against Gram-negative bacilli such combinations may be synergistic experimentally, but in such large doses that it is doubtful whether the results can be clinically applicable (Bach et al., 1966) . There is, however, much to be said for adding benzylpenicillin in large doses to cloxacillin or methicillin in the treatment of infections with penicillin-resistant staphylococci.
Acquired Drug Resistance
This term may be used to indicate that a strain of bacteria infecting a patient, and originally sensitive to a particular drug, has become resistant to that drug during treatment. At one time there was some controversy over whether acquired resistance was due to the differential growth of naturally occurring resistant mutants or to adaptation of all members of the strain to the drug (Mitchison, 1962) . To some extent the difference may be semantic in so far as "triggering" by the drug may be required to develop the full potential of resistance (De Courcy and Sevag, 1966) , and this might be interpreted as adaptation. Nevertheless it is a genetically determined capacity for adaptation, and the genetic basis of acquired resistance is now generally accepted.
Chemotherapeutic agents may be conveniently classified into two groups; to one resistance may be very rapidly acquired, to the other only slowly. In the case of the " slow " group, if organisms are repeatedly cultured in increasing concentrations of one of these drugs, subculturing on each occasion from the highest tube in which growth has occurred, the degree of resistance may be slowly pushed up. This small-step increase is probably due to mutations occurring in a number of genes, each of which is responsible for a slight increase in resistance. In at least one instance, that of chloramphenicol resistance, there is evidence that the genes may be distributed right along the chromosome. In experiments in which organisms made artificially resistant to varying degrees were cross-mated with sensitive organisms it was shown that the degree of resistance in the progeny depended on the amount of chromosome transferred (Cavalli and Maccacaro, 1952 (Mitchison, 1962) . Streptomycin resistance appears to consist in a structural change in the 30S subunit of the ribosome (Cox et al., 1964; Davies, 1964) , and to be controlled by genes in the bacterial chromosome rather than by cytoplasmic genetic material (Richmond, 1966) .
Clinical Significance of Acquired Resistance
It is important that the clinician should be familiar with the drugs to which resistance may be readily acquired, as, for reasons which are outlined below, such drugs should always be used in combination. In Resistance is rapidly acquired to almost all antituberculosis drugs if used alone, with the possible exception of cycloserine.
Rapidly acquired drug resistance is of great clinical importance and always a potential danger in the individual patient if one of these drugs is used alone. In general, strains rendered resistant in this way do not easily revert to sensitivity, though this is said to be commoner with erythromycin than with other drugs. The mechanism may be illustrated by pulmonary tuberculosis treated with a single drug. In any large population of "isoniazid-sensitive " tubercle bacilli about one in a million is a naturally occurring resistant mutant (Fig. 6) . Under natural conditions the proportion remains small probably because the resistant mutants are at a slight biological disadvantage compared with sensitive bacilli. If isoniazid is given alone the sensitive bacilli diminish in numbers and the isoniazid-resistant mutants are now at a biological advantage.
If the population is large and the patient's defences are poor, the resistant mutants may increase and ultimately replace the sensitive population. These resistant bacilli usually persist for the rest of the patient's life, and may indeed infect other people.
On the other hand, if both streptomycin and isoniazid are given to the patient (Fig. 7) , streptomycin affects not only the isoniazid-sensitive population but also the isoniazid-resistant mutants. There are also, of course, a small number of strepto- J1_ournal, 1969, 2, 141-145 Summary: The uptake of copper and zinc by patients undergoing regular haemodialysis has been assessed by measuring the dialysis fluid for copper and zinc concentration, and the blood entering and leaving the dialysis coil for red cell copper, plasma free copper, and plasma zinc levels during priming of the coil and subsequent haemodialysis, and by in-vitro studies.
Red cells avidly removed copper from dialysis fluid when mixed with saline during priming, but did not take up copper during the haemodialysis. At both these stages plasma actively took up both copper and zinc from dialysis fluid, even against a concentration gradient, so that loss of these metals from plasma to dialysis fluid did not occur.
In the dialysis systems investigated the sources of the copper in the dialysis fluid were the copper plumbing of the tap-water and the dialysis coil, and the major source of zinc was the zinc oxide of the adhesive plaster around the dialysis coil.
Introduction
Lyle (1967) demonstrated loss of copper from dialysis fluid during haemodialysis and suggested that uptake of copper by the patient may be contributing to the haemolytic anaemia of these patients.
We have investigated both copper and zinc during haemodialysis by measuring their concentrations in tap-water and dialysis fluid, in blood taken before entering the dialysing coil, and in blood returning to the patient from the coil after dialysis.
The aim was to determine whether copper and zinc are taken into the blood and whether this mechanism could lead to toxic amounts of these metals entering the blood. A further aim was to see whether the body could be depleted of these minerals by dialysing against low concentrations, in the same way that
